Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EPZM

Epizyme (EPZM) Stock Price, News & Analysis

Epizyme logo

About Epizyme Stock (NASDAQ:EPZM)

Advanced Chart

Key Stats

Today's Range
$1.47
$1.47
50-Day Range
$1.47
$1.52
52-Week Range
$0.41
$5.80
Volume
7,960 shs
Average Volume
3.23 million shs
Market Capitalization
$247.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Receive EPZM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter.

EPZM Stock News Headlines

bluebird bio Inc BLUE
"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
Epizyme: Q2 Earnings Insights - Benzinga
See More Headlines

EPZM Stock Analysis - Frequently Asked Questions

Epizyme, Inc. (NASDAQ:EPZM) announced its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.16. The business's quarterly revenue was up 45.8% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that Epizyme investors own include Novavax (NVAX), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), Pfizer (PFE), Applied Materials (AMAT) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/09/2021
Today
6/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EPZM
Employees
250
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$251.12 million
Net Margins
-391.90%
Pretax Margin
-391.80%

Debt

Sales & Book Value

Annual Sales
$37.43 million
Price / Cash Flow
N/A
Book Value
($0.54) per share
Price / Book
-2.72

Miscellaneous

Free Float
128,968,000
Market Cap
$247.44 million
Optionable
Optionable
Beta
-0.41

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:EPZM) was last updated on 6/5/2025 by MarketBeat.com Staff
From Our Partners